Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $119.00 | Total: $595.00 |
| 1 | 10 | $100.80 | Total: $1,008.00 |
| 1 | 25 | $85.40 | Total: $2,135.00 |
| 1 | 50 | $72.80 | Total: $3,640.00 |
| 1 | 100 | $63.00 | Total: $6,300.00 |
Overview
Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is a first-of-its-kind, orally active androgen receptor N-terminal structural domain (AR-NTD) inhibitor with anticancer activity and can be used to study prostate and breast cancer.
Chemical Properties
| Molecular Formula | C27H33ClO8 |
| Molecular Weight | 521 |
| CAS Numbers | 1637573-04-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC(=O)OC[C@H](COc1ccc(cc1)C(C)(C)c1ccc(OC[C@@H](CCl)OC(C)=O)cc1)OC(C)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2[6] 453-467. Published 2019 Sep 26.